Infectious Disease Control
KHB Becomes First Chinese Company to Obtain EU Class D IVDR Certification for Its Rapid Test HIV Colloidal Gold Diagnostic Kit
SHANGHAI, Oct. 11, 2023 /PRNewswire/ -- Shanghai Kehua Bio-engineering
2023-10-11 16:27
3465
Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre
TAIZHOU, China, Oct. 10, 2023 /PRNewswire/ -- On October 8, 2023, Dr. Deckster Tonny SAVADYE, CEO of Zimbabwe NBA, and Dr.Yang Yili, International Centre for Genetic Engineering and Biotechnology China Regional Research Centre(ICGEB), visited Recbio. Dr. SAVADYE and his team conducted an on-the-s...
2023-10-10 13:54
5581
Agilent and Sarawak Infectious Disease Centre Partner to Boost Neglected Tropical Diseases Research in East Malaysia
KUALA LUMPUR, Malaysia, Oct. 6, 2023 /PRNewswire/ -- Agilent Technologies Inc.
2023-10-06 13:26
4058
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
* This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. * Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid * Fin...
2023-10-04 04:25
4281
China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally
The documentary outlines China's contribution to vaccine science, research, and production since the COVID-19 pandemic and includes a call for science and infectious disease research to be borderless. BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese R...
2023-10-02 15:00
2930
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Everest Medicines
2023-09-28 07:38
2946
Global Times: China-Africa medical cooperation broadens under BRI
BEIJING, Sept. 4, 2023 /PRNewswire/ -- Tesfaye Hailemicheal and his colleagues have settled in the new headquarters of the Africa Centers for Disease Control and Prevention (Africa CDC) for over six months now. Hailemicheal still finds himself drawn to the meeting room across from his office. Fro...
2023-09-04 08:43
2091
Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress
TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023. During the reporting period, the company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", rapidly promoted pr...
2023-08-28 11:08
3673
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end ...
2023-08-22 22:00
4163
Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI)
SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase in...
2023-08-15 20:19
3608
TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan
Non-profit drug developer partners with leading manufacturer of medicine in Pakistan NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medici...
2023-08-14 21:30
2171
Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]
* First pneumococcal conjugate vaccine that fights against 20 serotypes leading to most of the invasive pneumococcal diseases and pneumonia[2],[3] — one of the leading causes of death inHong Kong[4] — has been approved by Hong Kong Department of Health inApril 2023 and is now available in Hong ...
2023-08-10 14:15
2389
![Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older[1]](https://mma.prnasia.com/media2/2155046/Pfizer.jpg?p=medium600)
World Hepatitis Alliance raise awareness of viral hepatitis on World Hepatitis Day as research shows hepatitis B and C cause significantly higher cancer risk than smoking a daily pack of cigarettes
LONDON, July 28, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'. On WHD, the World Hepatitis Alliance (WHA) joins together with its global network of 323 members in over 100 countries to lead the campaign internationally to accelerate th...
2023-07-28 04:02
2570
Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress
TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by National Medical Products Administration ("NMPA"), pursuant to which the c...
2023-07-27 10:57
5278
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...
2023-07-06 07:25
3886
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsA...
2023-07-06 07:19
4179
New Survey Reveals Insights on Singapore Workers' Preparedness for Digital Transformation
Study sheds light on perceptions, behaviours and changes towards digitalisation in the aftermath of the COVID-19 pandemic SINGAPORE, July 3, 2023 /PRNewswire/ -- Reeracoen, a leading provider of human resource services inSingapore, has released its latest report titled "Employee Attitudes Toward...
2023-07-03 07:45
2774
Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective
TB is one of the world's deadliest diseases, killing about 4,300 people per day, mostly those living in poverty LONDON and SEATTLE, June 29, 2023 /PRNewswire/ -- Wellcome and the Bill & Melinda Gates Foundation today announced funding to advance a tuberculosis (TB) vaccine candidate, M72/AS01E ...
2023-06-29 00:00
3420
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections Company returns Greater China rights to Qpex Biopharma of beta-lactamase inhibitor QPX7728-based products Company to receive ~$24M upfront cash payme...
2023-06-26 07:30
3475
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...
2023-06-25 20:00
4557
Week's Top Stories
Most Reposted
One Universal Production Group (OUP) Officially Opens, Reinforcing Its Position as Asia's Leading IP Ecosystem and Tourism Company
[Picked up by 315 media titles]
2025-12-20 09:36
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 275 media titles]
2025-12-26 12:55The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup
[Picked up by 270 media titles]
2025-12-21 12:42
Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 263 media titles]
2025-12-22 15:56
